(70 days)
Not Found
No
The device is a lateral flow immunoassay that provides qualitative results based on the presence or absence of colored lines. The mechanism described is based on antigen-antibody binding and does not involve computational analysis or learning algorithms.
No.
This device is for qualitative detection of drugs in human urine (diagnostic), not for therapy or treatment.
Yes
The device is described as a rapid chromatographic immunoassay for the qualitative and simultaneous detection of drugs in human urine, and clinical evaluation results are provided, which are indicators of a diagnostic device.
No
The device is a rapid chromatographic immunoassay, which is a physical test card/device that utilizes chemical reactions and visual interpretation. It does not involve software as its primary function.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "qualitative and simultaneous detection of two to six drugs in a variety of combinations in human urine." This involves testing a sample taken from the human body (urine) in vitro (outside the body) to provide diagnostic information (presence or absence of specific drugs).
- Device Description: The description details a "rapid chromatographic immunoassay" that utilizes "antigen-antibody immunochemistry" to detect substances in urine samples. This is a common method used in IVD tests.
- Performance Studies: The document describes a "clinical evaluation using clinical urine specimens" and comparison to "GC/MS analysis," which is a standard method for confirming the presence of substances in biological samples. This type of study is typical for validating the performance of an IVD.
- Predicate Devices: The listed predicate devices are all single-drug tests designed for detecting substances in urine, further indicating the IVD nature of this multi-drug test.
The core function of the device is to analyze a biological sample (urine) in vitro to provide information about the presence of specific substances, which is the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The ACON® One Step Multi-Drug Multi-Line Screen Test Card and Test Device are rapid chromatographic immunoassays for the qualitative and simultaneous detection of two to six drugs in a variety of combinations in human urine. The designated Cutoff concentrations for these drugs are as follows:
| Analyte | Abbreviation | Calibrator | Cutoff Conc. |
|---|---|---|---|
| Barbiturates | BAR | Secobarbital | 300 ng/mL |
| Benzodiazepines | BZO | Oxazepam | 300 ng/mL |
| Methadone | MTD | Methadone | 300 ng/mL |
| MDMA (Ecstasy) | MDMA | MDMA | 500 ng/mL |
| Opiates | MOP or OPI | Morphine | 300 ng/mL |
| Tricyclic Antidepressants | TCA | Nortriptyline | 1,000 ng/mL |
These tests are intended for healthcare professionals including professionals at the point of care sites.
Product codes (comma separated list FDA assigned to the subject device)
DJC; DJG; DJG; JXM; DJR; LFG
Device Description
The ACON One Step Multi-Drug Multi-Line Screen Test Card and Test Device are competitive binding, lateral flow immunochromatographic assays for the qualitative and simultaneous detection of Barbiturates, Benzodiazepines, Methadone, MDMA, Opiates and Tricyclic Antidepressants in urine samples. The test is based on the principle of antigenantibody immunochemistry. It utilizes mouse antibodies to selectively detect elevated levels of Barbiturates, Benzodiazepines, Methadone, MDMA, Opiates and Tricyclic Antidepressants in urine at Cutoff concentrations of 300 ng/mL (BZO), 1,000 ng/mL (TCA), 300 ng/mL (BAR), 500 ng/mL (MDMA), 300 ng/mL (MTD) and 300 ng/mL (MOP). These tests can be performed without the use of an instrument.
A positive urine specimen will not generate a colored-line for the specific drug tested in the designated test region. A negative urine specimen or a urine specimen containing of Barbiturates, Benzodiazepines, Methadone, MDMA, Opiates and Tricyclic Antidepressants at the concentrations below the designated cutoff levels will generate a colored-line in the designated test region for the drug. To serve as a procedural control, a colored-line will always appear at the control region, indicating that proper volume of specimen has been added and membrane wicking has occurred.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
healthcare professionals including professionals at point of care sites.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A clinical evaluation was conducted using clinical urine specimens. Over 1,000 clinical specimens were employed including approximately 10% of the samples with drug concentrations in the -25% to +25% Cutoff range. This evaluation compared the test results between the ACON One Step Multi-Line Screen Test Card and the Test Device versus previously FDA-cleared Barbiturates, Benzodiazepines, Methadone, MDMA, Opiates and Tricyclic Antidepressants Single tests; as well as against data obtained from the customary GC/MS analysis. Samples with drug concentration above the Cutoff level were considered presumptive positive and concentrations below the Cutoff are considered negative.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical evaluation using clinical urine specimens, samples size over 1000. No AUC or MRMC reported. Standalone performance not directly reported, but comparison to GC/MS analysis is provided.
Key results are comparisons of agreement with GC/MS analysis for both the ACON Test Card and ACON Test Device.
ACON Test Card vs. GC/MS Analysis:
BAR: Positive Agreement = 127/133 = 95% (90% - 98%), Negative Agreement = 160/160 = >99% (98% - 99%), Overall Agreement = 287 / 293 = 98% (96% - 99%)*
BZO: Positive Agreement = 128/131=98% (93% - 99%), Negative Agreement = 160/160=>99% (98% - 99%), Overall Agreement = 288/291= 99% (97% - 99%)*
MTD: Positive Agreement = 120/129 = 93% (87% - 97%), Negative Agreement = 177/177 = >99% (98% - 99%), Overall Agreement = 297 / 306 = 97% (97% - 99%)
MDMA: Positive Agreement = 86/87 = 99% (94% - 99%), Negative Agreement = 155/155 = >99% (98% - 99%), Overall Agreement = 241/242 = 99% (98% - 99%)*
MOP: Positive Agreement = 122/122 = >99% (97% - 99%), Negative Agreement = 157/160 = 98% (95% - 99%), Overall Agreement = 279/282 = 99% (97% - 99%)*
TCA: Positive Agreement = 34/34 = >99% (90% - 99%), Negative Agreement = 181/192 = 94% (90% - 97%), Overall Agreement = 215/226 = 95% (91% - 98%)*
ACON Test Device vs. GC/MS Analysis:
BAR: Positive Agreement = 124/133 = 93% (88% - 97%), Negative Agreement = 160/160 = >99% (98% - 99%), Overall Agreement = 284 / 293 = 97% (94% - 97%)*
BZO: Positive Agreement = 127/131=98% (92% - 99%), Negative Agreement = 160/160=>99% (98% - 99%), Overall Agreement = 287/291= 99% (97% - 99%)*
MTD: Positive Agreement = 120/129 = 93% (87% - 97%), Negative Agreement = 177/177 = >99% (98% - 99%), Overall Agreement = 297 / 306 = 97% (97% - 99%)
MDMA: Positive Agreement = 87/87 = >99% (96% - 99%), Negative Agreement = 154/155 = 99% (96% - 99%), Overall Agreement = 241/242 = 99% (98% - 99%)*
MOP: Positive Agreement = 122/122 = >99% (97% - 99%), Negative Agreement = 158/160 = 99% (97% - 99%), Overall Agreement = 280/282 = 99% (95% - 99%)*
TCA: Positive Agreement = 34/34 = >99% (90% - 99%), Negative Agreement = 181/192 = 94% (90% - 97%), Overall Agreement = 215/226 = 95% (91% - 98%)*
*95% Confidence Interval
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Positive Agreement, Negative Agreement, Overall Agreement.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
K012824, K012300, K012595, K022589, K011353, K021526
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.3150 Barbiturate test system.
(a)
Identification. A barbiturate test system is a device intended to measure barbiturates, a class of hypnotic and sedative drugs, in serum, urine, and gastric contents. Measurements obtained by this device are used in the diagnosis and treatment of barbiturate use or overdose and in monitoring levels of barbiturate to ensure appropriate therapy.(b)
Classification. Class II (special controls). A barbiturate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
8. 510(k) SUMMARY
This summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The Assigned 510(k) number is ________________________________________________________________________________________________________________________________________________
Submitter:
ACON Laboratories, Inc. 4108 Sorrento Valley Blvd. San Diego, California 92121
Tel.: 858-535-2030 Fax: 858-535-2038
Date: November 22, 2002
Contact Person: Edward Tung, Ph.D.
Product Names:
ACON One Step Multi-Drug Multi-Line Screen Test Card
ACON One Step Multi-Drug Multi-Line Screen Test Device
Common Name:
Immunochromatographic test for the simultaneously qualitative detection of Barbiturates, Benzodiazepines, Methadone, MDMA, Opiates and Tricyclic Antidepressants in urine.
Device Classification:
The ACON One Step Multi-Drug Multi-Line Screen Test Card and Test Device are similar to other FDA-cleared devices for the qualitative and simultaneous detection of Barbiturates, Benzodiazepines, Methadone, MDMA, Opiates and Tricyclic Antidepressants in urine specimens. These tests are used to provide a preliminary analytical result only. Benzodiazepines, Tricyclic Antidepressants, Barbiturates, MDMA, Methadone and Opiates test systems have been classified as Class II devices with moderate complexity.
Classification Name:
Barbiturate, Benzodiazepine, Methadone, MDMA, Opiate and Tricyclic Antidepressant test system
1
Intended Use:
The ACON® One Step Multi-Drug Multi-Line Screen Test Card and Test Device are rapid chromatographic immunoassays for the qualitative and simultaneous detection of two to six drugs in a variety of combinations in human urine samples. The designated cutoff concentrations for these drugs are as follows: Barbiturates at 300 ng/mL, Benzodiazepines at 300 ng/mL, Methadone at 300 ng/mL, Methylenedioxymethamphetamine (Ecstasy) at 500 ng/mL, Opiates at 300 ng/mL and Tricyclic antidepressant at 1,000 ng/mL. They are intended for healthcare professionals including professionals at point of care sites.
Description:
The ACON One Step Multi-Drug Multi-Line Screen Test Card and Test Device are competitive binding, lateral flow immunochromatographic assays for the qualitative and simultaneous detection of Barbiturates, Benzodiazepines, Methadone, MDMA, Opiates and Tricyclic Antidepressants in urine samples. The test is based on the principle of antigenantibody immunochemistry. It utilizes mouse antibodies to selectively detect elevated levels of Barbiturates, Benzodiazepines, Methadone, MDMA, Opiates and Tricyclic Antidepressants in urine at Cutoff concentrations of 300 ng/mL (BZO), 1,000 ng/mL (TCA), 300 ng/mL (BAR), 500 ng/mL (MDMA), 300 ng/mL (MTD) and 300 ng/mL (MOP). These tests can be performed without the use of an instrument.
A positive urine specimen will not generate a colored-line for the specific drug tested in the designated test region. A negative urine specimen or a urine specimen containing of Barbiturates, Benzodiazepines, Methadone, MDMA, Opiates and Tricyclic Antidepressants at the concentrations below the designated cutoff levels will generate a colored-line in the designated test region for the drug. To serve as a procedural control, a colored-line will always appear at the control region, indicating that proper volume of specimen has been added and membrane wicking has occurred.
Predicate Devices:
ACON™ Barbiturates, Benzodiazepines, Methadone, MDMA, Opiates and Tricyclic Antidepressants Single Drug Test strips were used as the predicate devices for the ACON® One Step Multi-Drug Multi-Line Screen Test Card and Test Device to compare their performance with clinical urine specimens.
| The 510(k) Numbers for these predicate devices are. | |
|---|---|
| ACON BAR One Step Barbiturates Test Strip | K012824 |
| ACON BZO One Step Benzodiazepines Test Strip | K012300 |
| ACON MTD One Step Methadone Test Strip | K012595 |
| ACON MDMA One Step MDMA Test Strip | K022589 |
| ACON MOP One Step Opiates Test Strip | K011353 |
| ACON TCA One Step Tricyclic Antidepressant Test Strip | K021526 |
The 510/k) Numbers for these predicate devices are
2
Comparison to a Predicate Device:
A comparison of the features of the ACON™ One Step Multi-Drug Multi-Line Screen Test Card and Test Device versus the ACON™ Barbiturates, Benzodiazepines, Methadone, MDMA, Opiates and Tricyclic Antidepressants Single Tests is shown below:
- Both tests are assays intended for the qualitative detection of Barbiturates, ● Benzodiazepines, Methadone, MDMA, Opiates and Tricyclic Antidepressants in urine samples.
- Both tests are intended as a screening method that provides a preliminary analytical test ● result.
- . Both tests are immunochromatographic, lateral flow assays for the rapid detection of Barbiturates, Benzodiazepines, Methadone, MDMA, Opiates and Tricyclic Antidepressants with a visual, qualitative end result, while ACON Multi-Drug Multi-Line Test detects 2 to 6 of the above drugs simultaneously.
- Both tests utilize the same basic immunoassav principles that rely on antigen/ antibody interactions to indicate a positive or negative result.
- Both tests have the same Cutoff for each drug test.
Safety and Effectiveness Data:
Accuracy
A clinical evaluation was conducted using clinical urine specimens. This evaluation compared the test results between the ACON One Step Multi-Line Screen Test Card and the Test Device versus previously FDA-cleared Barbiturates, Benzodiazepines, Methadone, MDMA, Opiates and Tricyclic Antidepressants Single tests; as well as against data obtained from the customary GC/MS analysis. Over 1,000 clinical specimens were employed including approximately 10% of the samples with drug concentrations in the -25% to +25% Cutoff range. The comparisons of data obtained from this study yielded the following results:
3
Clinical study results of ACON One Step Multi-Drug Multi-Line Screen Test Card and Test Device are compared to GC/MS analysis data:
The GC/MS Cutoff levels for each of the six drugs tested are as follows:
| Barbiturates (BAR) at | 300 ng/mL |
|---|---|
| Benzodiazepines (BZO) at | 300 ng/mL |
| Methadone (MTD) at | 300 ng/mL |
| MDMA (Ecstasy) at | 500 ng/mL |
| Opiates (MOP) at | 300 ng/mL |
| Tricyclic Antidepressants (TCA) at | 1,000 ng/mL |
Samples with drug concentration above the Cutoff level were considered presumptive positive and concentrations below the Cutoff are considered negative.
| ACON Test Card | Positive Agreement | Negative Agreement | Overall Agreement |
|---|---|---|---|
| BAR | 127/133 = 95% | ||
| (90% - 98%)* | 160/160 = >99% | ||
| (98% - 99%)* | 287 / 293 = 98% | ||
| (96% - 99%)* | |||
| BZO | 128/131=98% | ||
| (93% - 99%)* | 160/160=>99% | ||
| (98% - 99%)* | 288/291= 99% | ||
| (97% - 99%)* | |||
| MTD | 120/129 = 93% | ||
| (87% - 97%)* | 177/177 = >99% | ||
| (98% - 99%)* | 297 / 306 = 97% | ||
| (97% - 99%) | |||
| MDMA | 86/87 = 99% | ||
| (94% - 99%)* | 155/155 = >99% | ||
| (98% - 99%)* | 241/242 = 99% | ||
| (98% - 99%)* | |||
| MOP | 122/122 = >99% | ||
| (97% - 99%)* | 157/160 = 98% | ||
| (95% - 99%)* | 279/282 = 99% | ||
| (97% - 99%)* | |||
| TCA | 34/34 = >99% | ||
| (90% - 99%)* | 181/192 = 94% | ||
| (90% - 97%)* | 215/226 = 95% | ||
| (91% - 98%)* |
ACON One Step Multi-Drug Multi-Line Screen Test Card vs. GC/MS Analysis
- 95% Confidence Interval
4
| ACON Test Device | Positive Agreement | Negative Agreement | Overall Agreement |
|---|---|---|---|
| BAR | 124/133 = 93% | ||
| (88% - 97%)* | 160/160 = >99% | ||
| (98% - 99%)* | 284 / 293 = 97% | ||
| (94% - 97%)* | |||
| BZO | 127/131=98% | ||
| (92% - 99%) | 160/160=>99% | ||
| (98% - 99%) | 287/291= 99% | ||
| (97% - 99%)* | |||
| MTD | 120/129 = 93% | ||
| (87% - 97%)* | 177/177 = >99% | ||
| (98% - 99%)* | 297 / 306 = 97% | ||
| (97% - 99%) | |||
| MDMA | 87/87 = >99% | ||
| (96% - 99%)* | 154/155 = 99% | ||
| (96% - 99%)* | 241/242 = 99% | ||
| (98% - 99%)* | |||
| MOP | 122/122 = >99% | ||
| (97% - 99%)* | 158/160 = 99% | ||
| (97% - 99%)* | 280/282 = 99% | ||
| (95% - 99%)* | |||
| TCA | 34/34 = >99% | ||
| (90% - 99%)* | 181/192 = 94% | ||
| (90% - 97%)* | 215/226 = 95% | ||
| (91% - 98%)* |
A CON One Step Multi-Drug Multi-Line Screen Test Device vs. GC/MS Analysis
- 95% Confidence Interval
Conclusion:
Clinical study results demonstrate the substantial equivalency between the ACON One Step Multi-Drug Multi-Line Screen Test Card and Test Device and the Barbiturates, Benzodiazepines, Methadone, MDMA, Opiates and Tricyclic Antidepressants single tests, which have already been cleared by FDA and marketed in the United States. It is also demonstrated that these tests are safe and effective in detecting Barbiturates, Benzodiazepines, Methadone, MDMA, Opiates and Tricyclic Antidepressants at the following Cutoff concentrations: Barbiturates 300 ng/mL, Benzodiazepines 300 ng/mL, Methadone 300 ng/mL, MDMA 500 ng/mL, Opiates 300 ng/mL and Tricyclic Antidepressants 1,000 ng/mL. The physician's office laboratory POL study demonstrated that these tests are also suitable for use by professionals at point-of-care sites.
5
Image /page/5/Picture/1 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the top and left side. Inside the circle is a stylized image of three human profiles facing right, with flowing lines beneath them, possibly representing water or movement.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
FEB 0 5 2003
Edward Tung, Ph.D. Director of Regulatory Affair ACON Laboratories, Inc. 4108 Sorrento Valley Blvd. San Diego, CA 92121
Re: K023946 Trade/Device Name: ACON® One Step Multi-Drug Multi-Line Screen Test Card ACON® One Step Multi-Drug Multi-Line Screen Test Device Regulation Number: 21 CFR 862.3610 Regulation Name: Methamphetamine test system Regulatory Class: Class II Product Code: DJC; DJG; DJG; JXM; DJR; LFG Dated: November 25, 2002 Received: November 27, 2002
Dear Dr. Tung:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA). it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
6
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours.
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
7
INDICATIONS FOR USE 10.
510(k) Number: K023946
ACON® One Step Multi-Drug Multi-Line Screen Test Card Device Name:
ACON® One Step Multi-Drug Multi-Line Screen Test Device
Indications for Use:
The ACON® One Step Multi-Drug Multi-Line Screen Test Card and Test Device are rapid chromatographic immunoassays for the qualitative and simultaneous detection of two to six drugs in a variety of combinations in human urine. The designated Cutoff concentrations for these drugs are as follows:
| Analyte | Abbreviation | Calibrator | Cutoff Conc. |
|---|---|---|---|
| Barbiturates | BAR | Secobarbital | 300 ng/mL |
| Benzodiazepines | BZO | Oxazepam | 300 ng/mL |
| Methadone | MTD | Methadone | 300 ng/mL |
| MDMA (Ecstasy) | MDMA | MDMA | 500 ng/mL |
| Opiates | MOP or OPI | Morphine | 300 ng/mL |
| Tricyclic Antidepressants | TCA | Nortriptyline | 1,000 ng/mL |
These tests are intended for healthcare professionals including professionals at the point of care sites.
(Please do not write below this point) Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
Or
Over-The-Counter Use_
(Per 21 CFR 801.109)
Sean Compton
Division Sign-Off) Division of Clinical L 10k) Number